Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P51532 (
transcriptional activator
)
6,546
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Long noncoding RNAs (lncRNAs) regulating diverse cellular processes implicate in many diseases. However, the function of lncRNAs in cellular senescence remains largely unknown. Here we identify a novel long intergenic noncoding RNA Linc-ASEN expresses in prematurely senescent cells. We find that Linc-ASEN associates with UPF1 by RNA pulldown mass spectrometry analysis, and represses cellular senescence by reducing
p21
production transcriptionally and posttranscriptionally. Mechanistically, the Linc-ASEN-UPF1 complex suppressed
p21
transcription by recruiting Polycomb Repressive Complex 1 (PRC1) and PRC2 to the
p21
locus, and thereby preventing binding of the
transcriptional activator
p53 on the
p21
promoter through histone modification. In addition, the Linc-ASEN-UPF1 complex repressed
p21
expression posttranscriptionally by enhancing
p21
mRNA decay in association with DCP1A. Accordingly, Linc-ASEN levels were found to correlate inversely with
p21
mRNA levels in tumors from patient-derived mouse xenograft, in various human cancer tissues, and in aged mice tissues. Our results reveal that Linc-ASEN prevents cellular senescence by reducing the transcription and stability of
p21
mRNA in concert with UPF1, and suggest that Linc-ASEN might be a potential therapeutic target in processes influenced by senescence, including cancer.
...
PMID:A novel long noncoding RNA Linc-ASEN represses cellular senescence through multileveled reduction of p21 expression. 3181 56
<< Previous
1
2
3
4
5
6